No Data
No Data
Acelyrin Says Late-Stage Izokibep Trial Shows Statistically Significant Results
Acelyrin Spikes as Late-stage Data for Lead Asset Selected for Medical Event
Sector Update: Health Care Stocks Rise Premarket Thursday
Express News | ACELYRIN, Inc. Announces Positive Results From Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to Be Highlighted in Late-Breaking Oral Presentation at Eadv 2024
ACELYRIN, INC. Announces Positive Results From Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to Be Highlighted in Late-Breaking Oral Presentation at EADV 2024
Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc
No Data
No Data